Investors Can Still File Late Claims in Emergent BioSolutions Settlement

Court: D. Maryland

Case: 8:21-cv-00955

Investors can still file a late claim to receive payment from the $40M Emergent BioSolutions settlement.

What is this settlement?

EBS shareholders sued Emergent BioSolutions, claiming the company failed to maintain proper manufacturing standards, leading to the contamination of 15 million doses of Johnson & Johnson’s COVID-19 vaccine at its Baltimore plant.

Emergent BioSolutions has now agreed to settle by paying $40M to investors.

What can you do to recover your losses now?

You can submit your claim and be notified of any further updates.

More than 100 companies are currently paying out settlements. Connect your brokerage account to automatically check which ones you may have missed.